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Genome-wide association studies (GWAS) from the last several years have provided the
first unbiased evidence of the genes contributing to common cardiovascular disease traits in
European and some Asian populations. The results confirmed the importance of prior
knowledge, such as the central role of lipoproteins, but they also revealed that there is still
much to learn about the underlying mechanisms of this disease, as most of the associated
genes do not appear to be involved in pathways previously connected to atherosclerosis.
This review focuses on the common forms of the disease and looks at both human and
animal model studies. It summarizes what was known prior to GWAS, highlights how the
field has been changed by GWAS, and discusses future considerations, such as the
limitations of GWAS and strategies that may lead to a more complete, mechanistic
understanding of atherosclerosis.
Genetics and Atherosclerosis
Atherosclerosis is a progressive inflammatory disorder underlying coronary artery disease
(CAD) and stroke, major causes of mortality and morbidity worldwide. Figure 1 provides a
brief overview of the pathology of atherosclerosis. For a detailed description of the biology
of the disease, several recent reviews are available1-3. Most of our understanding of the
factors contributing to atherosclerosis has come from epidemiologic studies and from studies
of Mendelian forms of the disease, such as familial hypercholesterolemia. These have
revealed important roles for plasma lipoprotein, blood pressure, diabetes, and other risk
factors. The elaboration of pathways and mechanisms involved in the disease has relied
largely on animal models, particularly genetically engineered hypercholesterolemic
mice 4, 5. The vast majority of CAD and stroke is complex, involving multiple genetic and
environmental factors which, until recently, have largely resisted genetic dissection. Clearly,
a detailed mechanistic understanding of the genetic factors contributing to common forms
would have important implications for prevention and treatment of atherosclerosis 6.
This review is divided into three sections. The first summarizes efforts to understand the
genetics of common forms of atherosclerosis and its risk factors prior to the era of GWAS,
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before about 2007. In the next section, the results from recent GWAS are described and
placed in the context of what was previously known. Lastly, the third section discusses
efforts to go beyond association to an understanding of pathways and interactions. At
present, the outlook is promising, as the field appears to be poised to identify new genes and
new therapeutic targets for atherosclerosis.
Before GWAS
Measures of atherosclerosis, such as myocardial infarction, carotid intima-media thickness,
or coronary angiography, have very significant genetic components, as do risk factors such
as plasma lipid levels or blood pressure. Estimates of the heritability of the measures of
disease, based on familial clustering or twin studies, have varied widely but generally range
from 30-60% 4, 7, 8.
Prior to the GWAS era, efforts to identify genes contributing to atherosclerosis and other
complex diseases were largely restricted to studies of candidate genes or to analysis of
variations in experimental models, particularly mice and rats. Of the many case-control
candidate gene studies for CAD that were published, most were greatly underpowered and
few were convincingly replicated 9. An exception is the ABO locus, which was first
observed to be associated with CAD and thrombosis approximately 50 years ago 10. By
contrast, candidate gene studies for less complex and more accurately measured traits, such
as plasma lipoproteins, were relatively successful 11, 12. Particularly notable among the latter
were the identification the apolipoprotein(a) gene in the control of Lp(a) levels, the
apolipoprotein E gene in the control of plasma cholesterol and triglyceride levels, and the
apolipoprotein A5 gene in the control of triglyceride levels 11. A large nonparametric
(model-free) linkage study for common atherosclerosis in the Icelandic population identified
the gene for the lipoxygenase-associated protein 13, which was consistent with other studies
implicating the lipoxygenase pathway in atherosclerosis 14. Another linkage study, of the
familial combined hyperlipidemia trait, which is strongly associated with atherosclerosis,
identified the USF1 transcription factor gene 15. However, neither of these loci were
observed in subsequent very large lipid or atherosclerosis GWAS (see below). It is possible
that multiple, relatively rare alleles of these genes were responsible for the linkage findings,
in which case the loci might not exhibit significant associations with the common single
nucleotide polymorphisms (SNPs) studied in GWAS.
Inbred strains of mice exhibit significant differences in susceptibility to atherosclerosis and
lipoprotein metabolism, and linkage analyses of genetic crosses led to the robust mapping of
numerous quantitative trait loci (QTL) for atherosclerosis 16 (Table 1). The loci thus
identified tend to be large, often containing hundreds of genes, and they generally have very
modest effect sizes, usually explaining less than 5% of the overall variance in
atherosclerosis. Consequently, these studies (like QTL studies of most other complex traits)
have yielded few genes 16, 17. The most productive strategy to follow up QTL mapping has
been the construction of congenic strains of mice in which the QTL region of interest from
one parental strain is transferred, by a series of crosses, onto the background of the second
strain. The congenic region can then be subdivided without interference from separate loci
contributing to the trait. Such approaches have provided evidence for several genes
contributing to atherosclerosis, including apolipoprotein A-II 18, Ox40 ligand 19, and 5-
lipoxygenase 20. One gene identified in this way, zinc finger homeoboxes-2 (ZHX2) 21, 22,
was recently shown to be the most strongly associated gene with carotid-intima-media
thickness, a surrogate marker for atherosclerosis (see below).
In summary, prior to the GWAS era, before 2007, our understanding of the genetics of
atherosclerosis was based mostly on studies of candidate genes or rare, Mendelian traits. At
the time, the tremendous genetic complexity of atherosclerosis was not fully appreciated,
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and most human studies were underpowered. Studies in mice were only modestly successful
in identifying genes, although they did lead to the mapping of many loci and a
demonstration of considerable genetic complexity.
GWAS
The Human Genome Project, the HapMap Project, and subsequent genomic studies led to
the identification of many of the common SNPs in the world’s populations. The millions of
SNPs with minor allele frequencies of about 5% or greater fell into blocks exhibiting strong
linkage disequilibrium (LD) (that is, associations with one another) 23. With the
development of array technologies capable of simultaneously genotyping hundreds of
thousands of SNPs, it became possible to perform GWAS for common, complex traits,
including CAD and its risk factors (Table 2). Recently, various groups involved in such
studies have formed collaborations to perform meta-analyses on tens of thousands of
subjects 24, 25.
The largest GWAS for CAD, the CARDIoGRAM study, included over 100,000 subjects of
European descent 25 (Figure 2), and smaller CAD studies of Asian populations have also
been reported 26, 27. Altogether about 30 loci reaching statistical significance were
identified, with only slight evidence of ancestry-specific associations. All the loci exhibited
modest effect sizes, as the increased likelihood of developing the disease for individuals
carrying the risk allele as compared to those carrying the other allele (the “odds ratio”) was
generally less than 1.3. A number of the loci included well-known lipid genes such as LDLR
and PCSK9, supporting the importance of low density lipoprotines (LDL) in atherosclerosis.
A few others, such as CYPA1, CNNM2, and NT5C2, showed evidence of association with
hypertension, but most of the loci had no effects on known risk factors and were not
involved in pathways previously connected to atherosclerosis. This suggests that we are in
the dark about much of what contributes to the disease. It is also interesting that loci with
prominent effects on levels of high density lipoproteins (HDL), such as the CETP gene
locus 11, 12, did not exhibit significant association with atherosclerosis. Given the clear
protective effect of HDL in animal studies 11, 18, it seems likely that this reflects a lack of
power. The genes at most of the GWAS loci (Figure 2) are presently simply candidates (see
below) and, thus, we will not speculate here about their possible roles in atherosclerosis
except in the case of the few genes where there has been follow-up or additional
information.
Because of LD, it has proven difficult to definitively identify the causal genes at such loci
and, in some cases, it is clear that the SNP showing peak association resides many kilobases
away from the causal gene. One locus with a strong effect on both CAD and lipids contained
3 genes in LD (SELSR2, PSRC1 andSORT1), none of which were previously known to
participate in lipid metabolism. Mechanistic studies in tissue culture and mice identified
SORT1 as causal and implicated it in the production of VLDL 28. In this and other studies
(see below), analysis of gene expression in tissues has provided evidence for the
involvement of a gene in atherosclerosis
In such CAD GWAS, a locus on chromosome 9p21 has proven to be most strongly
associated with CAD 29-35. The locus also shows association with aneurysms but does not
affect plasma lipid levels 36. The LD block includes only a large noncoding RNA termed
ANRIL, and the expression of certain ANRIL splice forms in blood monocytes is associated
with the peak SNPs 32. The ANRIL transcript overlaps with some adjacent genes, including
some that regulate cell cycle, suggesting that variations in ANRIL expression may affect
these genes in cis 32. A mouse QTL for atherosclerosis exhibited altered expression of one
of these genes, Cdkn2a, and mice deficient in Cdkn2a exhibited increased atherosclerosis as
well as increased monocyte proliferation 37. The region of association is highly enriched for
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predicted enhancers and two of the peak SNPs disrupt interferon signaling by preventing the
binding of the STAT1 transcription factor, suggesting an inflammatory mechanism 38. Thus,
although some tantalizing clues have been uncovered, the mechanism by which the 9p21
locus modulates cardiovascular risk remains unclear.
Genetic-epidemiologic studies have shown that the heritability of CAD tends to decrease
with the age of the population being studied and, thus, early myocardial infarction should be
a particularly informative and clinically significant phenotype. A study of 2967 cases and
3075 controls consisting of men less than 50 years old and women less than 60 years old
revealed some of the same loci as observed in the larger CAD studies but no novel loci 33. In
addition to SNPs, that study examined copy number variants but failed to identify any
additional associations. Thus, whereas copy number variants appear to be very important in
certain disorders, such as autism, this is likely not the case for atherosclerosis.
Another study used coronary angiographic phenotyping to perform case/control GWAS 39.
A total of 12,393 individuals with angiographic CAD were compared with 7383 healthy
individuals. None of the loci identified were novel as compared to the large CAD GWAS
discussed above. In the second part of the study, the authors tested whether genetic factors
contributed distinctly to the development of coronary atherosclerosis as compared to
myocardial infarction (MI). While the most common cause of MI is plaque rupture, MI is
not well correlated with the extent of lesions 1. This is likely due to the fact that lesion
rupture is more a function of the quality of lesions (fatty versus fibrous) rather than their size
(Figure 1). A group of subjects from the first group that had a MI (n=5783) was compared
with a group with no MI (n=3644). This analysis suggested that the ABO locus specifically
contributes to MI, contrasting with other loci, such as ADAMTS7 and 9p21, which appear to
impact primarily lesion development. Consistent with these findings, a previous study
showed that the “A” and “B” phenotypes (as compared to “O”) were associated with
thromboembolism and MI but not angina 40. The ABO gene encodes glycosyl transferases,
with the recessive O allele lacking activity. The O allele was associated in a GWAS with
reduced circulating von Willebrand Factor and Factor VIII coagulation factors 39, suggesting
that the association of this locus with CAD reflects at least a partial role for the modulation
of thrombosis in atherosclerosis.
Carotid-intima media thickness (cIMT) and carotid plaque determined by ultrasonography
are established measures of subclinical atherosclerosis. A recent meta-analysis of association
data in over 40,000 Europeans identified three loci for cIMT and two loci for carotid
plaque41. Only one of the nearby genes, EDNRA, encoding the endothelian receptor type A,
also showed association with CAD, as well as with high blood pressure. One of the novel
genes exhibiting association with cIMT is ZHX2. Studies in mice with a naturally occurring
null mutation exhibited a striking effect on aortic atherosclerosis 21, 22. The lack of overlap
between these measures of cIMT and CAD is surprising, suggesting specificity of artery
type or stage of disease 42. Studies in mice have revealed clear differences in genetic
contributions to lesion development between different arteries 43, and one study suggested
that aortic arch curvature contributes to susceptibility 44.
In all of these studies, the fraction of total phenotypic variance explained by the associated
SNPs was relatively small. The lead SNPs in the CARDioGRAM study, with over 100,000
Europeans, explained in aggregate about 10% of the additive genetic variance of CAD,
assuming the latter is 40% of the total. Even for the highly quantitative traits of plasma
lipoprotein levels, for which 95 significant loci have been identified, the fraction of variance
explained was small 12. The nature of the “missing heritability” for CAD and other common
diseases is unclear. Undoubtedly, it is due in part to many genes with effect sizes too small
to reach statistical significance in a GWAS design. Rare variants, some with large effect
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sizes, will also certainly contribute 45. Analysis of rare variants using exome sequencing,
new SNP chips with less common variants, and SNP chips designed to examine candidate
genes is underway. Finally, a recent study 46 pointed out that heritability estimates assume
an additive mode of inheritance, and if epistasis (i.e., a nonadditive interaction between
genes) is prevalent, as animal studies suggest 47, the estimates may be considerably inflated.
Thus, there may be much less “missing heritability” (that is, the additive fraction), than
widely assumed. Filling in the remainder (the nonadditive fraction) will be difficult in
human studies due to low power.
CAD typically affects men at an earlier age than women, and a recent study explored the
possible role of Y chromosome variation in this sexual dimorphism 48. The authors studied
various haplogroups of the Y chromosome in several thousand British men and observed
that one of the common haplogroups exhibited a 50% higher age-adjusted risk of CAD than
did men with other Y chromosome lineages (odds ratio 1.56, p = 0.0002). The association
between the haplogroup and increased CAD was independent of traditional and
socioeconomic risk factors. Analysis of macrophage transcriptomic data in a subset of the
men revealed differential gene expression in men with the risk haplogroup as compared to
other Y chromosome lineages. These genes were highly enriched for pathways contributing
to inflammation and immunity, suggesting a potential mechanism for the association.
Current Studies and Future Prospects
The major goals of genetic studies of cardiovascular disorders are to develop improved
preventative measures and more effective treatments. These will best be accomplished
through an understanding of the detailed mechanisms underlying the traits. An important
lesson of genetic studies thus far is that there is a great deal that we do not know about the
fundamental processes involved in CAD. For example, the genes at loci identified in the
very large CARDioGRAM CAD study (Figure 2) are mostly novel, with no known
connection to atherosclerosis. Clearly, some important on-going and future tasks are to: i)
identify the causal genes and DNA variants at the GWAS loci; ii) characterize the functions
of the causal genes; iii) extend the search to rare variants. Beyond that are a number of
specific questions that may be addressed by genetic studies (Box 1).
GWAS identify genes out of context, and to establish their functions in disease is likely to
be very challenging. For example, common variants of APOE were shown to be related to
late-onset Alzheimer’s disease nearly 20 years ago, but the mechanisms involved remain
hypothetical. Clearly, the genes can be studied in mice using transgenic or knockout models,
but whether this will provide meaningful answers is uncertain. The common variants
identified thus far are likely to influence the structures or expression levels of the gene
products very modestly, and the effects may well be nonlinear or dependent on interactions
with other variants. A case in point is the contrasting results obtained with over- or under-
expression of the SORT1 gene in mice 28, 49. Moreover, it is not clear that certain processes,
such as lesion rupture, can be adequately recapitulated in models such as mice or rats.
An alternative approach to understanding mechanisms in complex traits is “systems
genetics”. In this approach, intermediate molecular phenotypes and clinical phenotypes are
analyzed together in association or linkage studies 50-52. Through the use of high-throughput
technologies such as expression arrays, deep sequencing of RNA, or liquid chromatography/
mass spectrometry analysis of proteins and metabolites, the relationships of DNA variation,
molecular processes, and clinical traits can be integrated using mapping, correlation, and
mathematical modeling. In essence, systems genetics provides a means of determining the
molecular biological effects downstream of a genetic variant as well as interactions with
other variants and with environmental factors.
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Systems genetics requires that relevant tissue samples be collected from subjects along with
DNA, and this presents a problem in human studies. White cells from the blood have proven
useful for examining certain traits, such as the effects of 9p21 alleles and Y chromosome
haplogroups on gene expression, as discussed above. Another case in point is LIPA, the
lysosomal acid lipase gene, whose risk allele is strongly associated with increased
expression levels of LIPA mRNA in circulating monocytes 53. Biopsies or autopsy samples
of liver or adipose tissue have also been used to examine the effects of SNPs on the
expression of genes at candidate loci 28.
In addition to the study of single genes, intermediate phenotypes can be used to model
biologic networks 42, 54. A recent study 51 examined the effects of oxidized phospholipids
on human endothelial cell (EC) expression patterns in 162 primary cell lines to model
networks and pathways likely to be important in the initiation of inflammation in
atherosclerosis (Figure 3). This study revealed widespread occurrence of gene-by-
environment interactions and it generated hundreds of hypotheses. Such network models are
crude in several respects (for example, they assume that co-expression is a good measure of
shared functions), but they can be refined by targeted experimental perturbations. The long-
term goal is to develop multi-scale network models that integrate orthogonal datasets (such
as transcriptomic, proteomic, and metabolomic).
Blood metabolites are are proving to be another informative intermediate phenotype with
respect to CAD 55. Particularly striking was the finding that the metabolite trimethylamine-
N-oxide (TMAO) is strongly associated with atherosclerosis in human populations as well
as inbred strains of mice 56. TMAO appears to promote the formation of foam cells
(macrophages engorged with cholesterol) 56. TMAO is produced by the enzymatic oxidation
of trimethylamine 57, a gas produced in the intestine by the action of gut bacteria during the
breakdown of choline. TMAO levels are determined by diet, variations in expression of
flavin monooxygenases (enzymes that convert TMA to TMAO) and, very likely, variations
in the composition of gut flora 58.
As discussed above, QTL studies of cardiovascular traits in mice have been only modestly
successful, largely due to the difficulty of identifying causal genes following the mapping of
loci. Nevertheless, it is clear that there is a great deal of variation among inbred strains that
is relevant to CAD and related traits (Table 1). Of the QTL for aortic atherosclerosis that
have been robustly mapped in mice (Table 1), most do not harbor genes identified in human
GWAS. Thus, if the underlying genes could be identified, it would greatly add to our
understanding of the pathways involved in lesion development. In addition to
atherosclerosis, a variety of clinically relevant cardiovascular traits, such as aneurysms,
intima formation, and vascular calcification have been mapped in mice 59.
Recently, methods for high resolution mapping of complex trait loci in mice using
association analysis of outbred stocks or inbred strains (as contrasted to linkage) have been
developed 60. In particular, a panel of about 100 common inbred stains and recombinant
inbred strains, the Hybrid Mouse Diversity Panel (HMDP), was shown to have sufficient
power to map loci explaining as little as a few percent of the overall trait variance with about
an order of magnitude better resolution than linkage analysis 58, 61. Moreover, because the
strains are permanent, data generated from the HDMP are cumulative, and gene-by-
environment interactions can be analyzed, ideal for a systems genetics resource. Other
resources, such as the Collaborative Cross 62 also promise to revitalize the use of mice in the
analysis of complex traits.
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GWAS of large human populations have identified numerous novel genes/loci for
atherosclerosis and related traits. Individually, these loci have very modest effects on
disease, with typical odds ratios of 1.3 or less, limiting their predictive value. Despite the
modest effect sizes, the genes have the potential to reveal new disease pathways and new
targets for therapeutic intervention. However, human GWAS have some important
limitations. First, they have low power to identify gene-by-gene environment interactions 46.
Second, in aggregate, even very large GWAS have explained only a small fraction of the
estimated heritability (although, as discussed above, the additive component of heritability
may be inflated). Third, it is difficult in humans to follow up association results to identify
the pathways and mechanisms contributing to disease. Animal studies and systems-based
approaches are likely to be crucial in overcoming these limitations.
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-What pathways contribute to the initiation and propagation of inflammation in
atherosclerosis?
-What are the genetic factors contributing to plaque stability?
-How important are rare mutations with large effect size in common forms of
atherosclerosis?
-How important is epistasis in disease susceptibility?
-How can current knowledge of atherosclerosis be translated into prevention and
treatment?
-How well do animal studies model human disease?
-How important is maternal environment and epigenetics in atherosclerosis?
-How do diabetes and environmental factors such as air pollution contribute to
atherosclerosis?
-How does trimethylamine-N-oxide promote CAD?
-How do gut flora contribute to atherosclerosis?
-What is the basis of sex differences in atherosclerosis?
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Figure 1. Stages of coronary artery disease
Large arteries are bounded on the luminal side by a monolayer of endothelial cells that form
tight junctions, insulating the vessel wall from the blood. Underlying that is a region termed
the intima, that consists largely of proteoglycans and collagen. This is followed by layers of
smooth muscle cells, and then an outer region, the adventitia, consisting of fibrous elements
and fibroblasts. The first stages of atherosclerosis are characterized by the accumulation of
lipoproteins, particularly low density lipoproteins (LDL), in the intimal region. In response
to the lipoprotein accumulation, monocytes, and subsequently, lymphocytes, infiltrate the
vessel wall. The monocytes differentiate to macrophages which then take up the lipoproteins
to give rise to cholesterol-engorged “foam cells”, a hallmark of early atherogenesis. Some of
these foam cells eventually die, resulting in a necrotic core of cholesterol and cellular debris.
This is accompanied by the migration and proliferation of smooth muscle cells, which form
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a fibrous cap that overlies the necrotic core. The most common cause of a myocardial
infarction (MI) is the rupture of an atherosclerotic lesion, exposing tissue factor and leading
to the formation of a thrombus that blocks the flow of blood. In general, a thick fibrous cap
appears to protect against such rupture (from 7)
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Figure 2. GWAS of CAD in >100,000 Europeans
The Y axis shows the significance of the SNP association with CAD (as the negative of the
log10 or the P value), while the X axis shows the location of the SNP across the genome,
with Chromosomes shown in alternate colors. The most likely candidate genes at the
identified loci are indicated using gene symbols and the floating horizontal line represents
genome-wide significance using a Bonferroni adjustment. The names of the genes, in
alphabetical order, are as follows: ABO, ABO blood group (transferase A, alpha 1-3-N-
acetylgalactosaminyl-transferase B, alpha 1-3-galactosyltransferace); ADAMTS7, ADAM
metallopeptidase with thrombospondin type motif 1; ANKS1A, (ankyrin repeat and sterile
alpha motif domain containing A1; APOA5-A4-C3-A1, Apolipoprotein A5, A4, C3, A1
gene cluster; CDKN2A, cyclin-dependent kinase inhibitor 2A; CDKN2B, cyclin-dependent
kinase inhibitor 2B; COL4A1, collagen, type IV, alpha 1; COL4A2, collagen, type IV,
alpha 2; CNNM2, cyclin M2; CXCL12, chemokine (C-X-C motif) ligand 12; CYP17A1,
cytochrome P450, family 17, subfamily A, polypeptide 1; CYP46A1, cytochrome P450,
family 46, subfamily A, polypeptide 1; HHIPL1, hedgehog interacting protein-like 1;
LDLR, low density lipoprotein receptor; LPA, lipoprotein, Lp(a); MIA3, melanoma
inhibitory activity family, member 3; MRAS, muscle RAS oncogene homolog; MRPS6,
mitochondrial ribosomal protein S6; NT5C2, 5′-nucleotidase, cytosolic II; PCSK9,
proprotein convertase subtilisin/kexin type 9; PEMT, phosphatidylethanolamine N-
methyltransferase; PHACTR1, phosphatase and actin regulator 1; PPAP2B, phosphatidic
acid phosphatase type 2B; RASD1, RAS, dexamethasone-induced 1; SH2B3, SH2B adaptor
protein 3; SMG6, smg-6 homolog, nonsense mediated mRNA decay factor, SORT1, sortilin
1; TCF21, transcription factor 21; UBE2Z, ubiquitin-conjugating enzyme E2Z; WDR12,
WD repeat domain 12; ZC3HC1, zinc finger, C3HC-type containing 1; ZNF259, zinc
finger protein 259. (Reprinted from 25 with permission)
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Figure 3. Systems genetics analysis of human endothelial inflammatory response to oxidized
phospholipids
Atherosclerosis is initiated by the accumulation of lipoproteins in the vessel wall. The
phospholipids and cholesterol can undergo oxidative modification to produce a variety of
molecular species, some of which have potent pro-inflammatory activities. In this study,
model oxidized phospholipids were used to treat 162 primary human aortic endothelial cell
lines, and global transcript levels were determined for treated and control cultures using
expression arrays. About 2,000 genes whose expression levels were perturbed by the
treatment were used to model a co-expression network using the WGCNA algorithm. A total
of 11 subnetwork “modules” of highly connected genes were identified (Panel A) and most
were found to be highly enriched for certain known pathways such as cell cycle (shaded
green) and the unfolded protein response (shaded purple). Examination of the connections of
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genes within the modules identified novel pro-inflammatory pathways and regulatory
interactions. Shown in Panel (B) is a representation of the purple module (indicated by an
arrow) enriched for unfolded protein response genes, with darker colored modules indicating
hub nodes, and the length of the edges inversely related to the co-variation. Reprinted
from 51, with permission.
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Quantitative trait loci for atherosclerosis in mice.*
Chromosome(Mb) Cross Lod Reference
1(76) (C57BL/6J Apoe-/- x C3H/HeJ Apoe-/-)F2 6.5 63
1(82) B x H and C x B RI lines — — 64, 65
1(105) (12956/SuEuJac Apoe-/- x C57BL/6J Apoe-/-
)F2
5.0 44
1(160) (C57BL/6J Apoe-/- x C3H/HeJ Apoe-/-)F2 7.1 63
1(163) (12956/SuEuJac Apoe-/- x C57BL/6J Apoe-/-
)F2
6.8 44
2(38) (C57BL/6J Ldlr-/- x BALB/cByJ Ldlr-/-)F2 6.2 66
4(149) (MOLF x C57BL/6J-Ldlr-/-) x B6-Ldlr-/- 6.2 67
4(150) (C57BL/6J Apoe-/- x C3H/HeJ Apoe-/-)F2 5.0 63
6(127) (CAST x C57BL/6J)F2 6.7 68
6(136) (MOLF x C57BL/6J-Ldlr-/-) x C57BL/6J-
Ldlr-/-
6.7 67
7(62) (C57BL/6J Apoe-/- x C3H/HeJ Apoe-/-)F2 6.6 63
9(46) (C57BL/6J Apoe-/- x C3H/HeJ Apoe-/-)F2 5.0 63
9(61) 12956/SuEuJac Apoe-/- x C57BL/6J Apoe-/-)F2 6.9 44
9(84) (C57BL/6J Apoe-/- x C3H/HeJ Apoe-/-)F2 8.1 63
10(20) (C57BL/6J.129-Apoe-/- x FVB.129-Apoe-/-)F2 5.1 69
10(21) (C57BL/6J.129-Ldlr-/- x FVB.129-Ldlr-/-
)RpF2
13.1 70
10(55) (C57BL/6J x DBA/2)F2 4.5 71
10(67) (C57BL/6J x 129)F2 6.6 72
11(104) (C57BL/6J Apoe-/- x C3H/HeJ Apoe-/-)F2 7.8 63
12(55) (B6 Ldlr-/- x FVB Ldlr-/-)RpF2 4.8 70
13(90) (C57BL/6J Apoe-/- x C3H/HeJ Apoe-/-)F2 7.0 63
15(71) (C57BL/6J Apoe-/- x C3H/HeJ Apoe-/-)F2 6.2 63
15(96) (129S6/SuEuJac Apoe-/- x C57BL/6J Apoe-/-
)F2
4.7 44
17(26) (C57BL/6J Apoe-/- x C3H/HeJ Apoe-/-)F2 4.3 63
17(36) (AKR Apoe-/- x DBA/2 Apoe-/-)RpF2 4.3 73
*
Unless otherwise indicated, the data are taken from 16. The location of the QTL peak on a chromosome is given in megabases (Mb). RI,
recombinant inbred; F2, intercross; “RpF2”, reciprocal F2 cross. Only QTL with lod score values that are significant genome-wide are included. A
lod score is a statistical measure of the significance of linkage. It is the log base10 of the “odds ratio” which is the probability of the data given a
linkage model divided by the probability of the data given the null hypothesis of no linkage.















GWAS of CAD and risk factors
Trait Population Number of
subjects
Reference
Early onset MI European 19,492 33




CAD Icelandic >17,000 31
CAD European >7,300 35




CAD Chinese Han >6,000 27
CAD European >100,000 25
Blood lipids European >100,000 12
Blood pressure European, others >200,000 57
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